Romosozumab is being developed as a novel therapy for osteoporosis. It is a monoclonal antibody that binds sclerostin, and has been shown to increase bone formation while decreasing bone resorption.
2016 has been a big year for biosimilars in rheumatology.
The anti-IL-12/IL-23 inhibitor, Stelara (ustekinumab) has been FDA approved for the treatment of psoriasis and psoriatic arthritis. In the last week, the EMA's CHMP has recommended that the drug also be approved for use in Crohn's disease.
Dr. Jack Cush reviews highlights, news and articles from the past week at RheumNow.com:
The world of PID (Primary immunodeficiency diseases) has changed remarkably over the past 5 years.
JAMA has reported the results of a 24-month trial showing that obese individuals on a long-term healthy diet and exercise program do not have significantly more weight loss from using a wearable device that tracks their activity.
A recent review has shown that tumor necrosis factor-α inhibitors (TNFi) rarely cause MS-like disorders.
The osteoporsis therapeutics arena is starting to fill with new drugs and novel mechanisms of action.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
